Evidence map›Paper›PMID 35011321›Full record

ArticleMolecules (Basel, Switzerland)2021

Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin.

Ashraf N Abdalla, Miriana Di Stefano, Giulio Poli, Tiziano Tuccinardi, Ammar Bader, Antonio Vassallo, Mohamed E Abdallah, Mahmoud Zaki El-Readi, Bassem Refaat, Alanood S Algarni and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Ashraf N AbdallaCollege of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-4770-9319
Miriana Di StefanoDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-6727-5816
Giulio PoliDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-8061-5632
Tiziano TuccinardiDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-6205-4069
Ammar BaderCollege of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-2201-7201
Antonio VassalloDipartimento di Scienze, Università Degli Studi della Basilicata, 85100 Potenza, Italy.ORCID 0000-0001-7937-3309
Mohamed E AbdallahDepartment of Clinical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Mahmoud Zaki El-ReadiDepartment of Clinical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0001-8398-5412
Bassem RefaatDepartment of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-4267-1016
Alanood S AlgarniCollege of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0002-2021-8731
Rizwan AhmadNatural Products and Alternative Medicines, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.ORCID 0000-0001-6490-8219
Hamad M AlkahtaniCollege of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-6983-8587
Alaa A-M Abdel-AzizCollege of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-3362-9337
Adel S El-AzabCollege of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Aljawharah AlqathamaCollege of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-0855-2013
Umm al-Qura University · SAKing Saud University · SAUniversity of Pisa · ITAl-Azhar University · EGImam Abdulrahman Bin Faisal University · SAUniversity of Basilicata · IT

Funding

Umm al-Qura University 19-MED-1-02-0004
6 · The paper itself

Abstract

Breast cancer is a complex and multi-drug resistant (MDR) disease, which could result in the failure of many chemotherapeutic clinical agents. Discovering effective molecules from natural products or by derivatization from known compounds is the interest of many research studies. The first objective of the present study is to investigate the cytotoxic combinatorial, chemosensitizing, and apoptotic effects of an isatin derived compound (5,5-diphenylimidazolidine-2,4-dione conjugated with 5-substituted isatin, named HAA

Indexed as

Antineoplastic AgentsApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Binding SitesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmHSP90 Heat-Shock ProteinsHumansInhibitory Concentration 50IsatinMCF-7 CellsModels, MolecularAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1DoxorubicinHSP90 Heat-Shock ProteinsIsatinapoptosisHsp90isatinMDRmolecular docking and dynamicsP-gpSPRsynergism with doxorubicin

Identifiers

PMID35011321
PMCPMC8746493
OpenAlexW4206137679

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.